Business Context and Reporting Period
This Form 6-K filing covers the month of December 2024 for Meiwu Technology Company Limited, a British Virgin Islands company. The report details a strategic pivot from its previous operations into the functional skincare business and the divestiture of its legacy corporate structure.
Key Financial Metrics and Transactions
- Revenue: The Company entered a sales agreement in Q4 2024 for functional skincare products totaling RMB 250,000.
- Asset Disposition: The Company sold 100% of the equity interests in two wholly-owned subsidiaries, Magnum International Holdings Limited and Xinfuxin International Holdings Limited, for $10 each.
- Liabilities: Upon closing the dispositions, the Purchaser assumed all assets and liabilities of the sold subsidiaries.
- Cash Flow, Margins, and Debt: The filing text does not provide clear values for operating cash flow, profit margins, or total debt levels.
Material Changes Versus Prior Period
- Business Model Transition: The Company has shifted focus to functional skincare, establishing a new PRC entity (Xiamen Chunshang Health Technology Co., Ltd.) and securing initial sales.
- Corporate Structure: The Company terminated its Variable Interest Entity (VIE) contractual arrangements with Meiwu Zhishi Technology (Shenzhen) Co., Ltd. on December 10, 2024.
- Divestitures: The Company exited its legacy holdings by selling Magnum and Xinfuxin to an unaffiliated Purchaser, closing the transactions on December 24 and December 31, 2024, respectively.
Outlook, Risks, and Management Commentary
Management indicates a strategic transition to expand into functional skincare sales. The Company has taken preliminary steps including trademark acquisition and distributor agreements. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks and uncertainties beyond the Company's control. No specific financial guidance or quantitative outlook was provided in this text.
Investor Verification Checklist
- Verify the financial health and solvency of the new skincare subsidiary, Xiamen Chunshang Health Technology Co., Ltd.
- Confirm the specific assets and liabilities transferred to the Purchaser in the Magnum and Xinfuxin dispositions to ensure no hidden contingent liabilities remain with the Company.
- Assess the scalability of the initial RMB 250,000 skincare sales agreement and the reliability of the third-party manufacturer.
- Review the full text of the Termination Agreement (Exhibit 10.1) to confirm the complete dissolution of VIE obligations.